|
| Reference | Age | Sex | Disease | Treatment | Follow-up |
|
| Griesinger et al. [2] | 63 | F | CML-like MPD, myeloid blast crisis | Imatinib, hydroxyurea, interferon-alpha | Complete hematological response. 20 months after diagnosis, she developed myeloid blast crisis and died. |
| Kantarcioglu et al. [3] | 64 | F | MDS | Not described | Died 3 months after diagnosis |
| Cuesta-Domínguez et al. [4] | 58 | M | B-ALL | Not described | Not described |
| Cirmena et al. [5] | 67 | F | AML | Not described | Not described |
| Tirado et al. [6] | 14 | M | B-ALL | Not described | Not described |
| Snider et al. [7] | 59 | M | MPN with eosinophilia, MPAL | Hydroxyurea, chemotherapy, allo-SCT | Transformation to MPAL 12 months after diagnosis. No evidence of disease 30 days after allo-SCT. |
| Elnaggar et al. [8] | 84 | M | CML-like MPD | Imatinib | Lost to follow-up |
| Schwaab et al. [10] | n/a | n/a | Myeloid neoplasm | Ruxolitinib 20 mg BID, allo-SCT | Complete hematological and cytogenetic remission on ruxolitinib. Relapsed after 18 months upon which referred for allo-SCT. |
| Schwaab et al. [11] | 69 | M | MDS/MPN | Ruxolitinib 20 mg BID, allo-SCT | Complete hematological, cytogenetic, and molecular response. AlloSCT while in remission |
| He et al. [14] | 36 | F | MPN with eosinophilia | Dasatinib, allo-SCT | No response of dasatinib. No evidence of disease 18 months after allo-SCT. |
| Bellesso et al. [15] | 54 | M | BCR-ABL- CML | Imatinib, dasatinib, allo-SCT | No response of imatinib or dasatinib. Died of aGvHD 53 days after allo-SCT |
| Impera et al. [16] | 49 | F | MPN-unclassifiable | Imatinib, dasatinib peg-interferon | No initial response with imatinib or dasatinib. Partial hematological response with peg-interferon |
| Lane et al. [17] | 44 | M | Atypical CML with leukemia cutis | Not described | Not described |
| Thakral et al. [18] | 31 | M | MPN with eosinophilia | Hydroxyurea, allo-SCT | No evidence of disease three months posttransplantation |
|
